Abstract
IntroductionWarfarin is a potent anticoagulant used for the prevention and treatment of venous and arterial thrombosis. Occasionally, patients require emergent warfarin reversal due to active bleeding, supratherapeutic international normalized ratio, or emergent diagnostic or therapeutic interventions. Various agents can be used for emergent warfarin reversal, including fresh frozen plasma (FFP) and 4-factor prothrombin complex concentrate (4F-PCC). Both FFP and 4F-PCC are generally considered safe; however, both agents contain coagulation factors and have the potential to provoke a thromboembolic event. Although clinical trials have compared the efficacy and safety of FFP and 4F-PCC, data are limited comparing the risk of thromboembolism between the two agents.MethodsA retrospective chart review was performed at a single, urban, academic medical center comparing the incidence of thromboembolism with FFP or 4F-PCC for warfarin reversal during a three-year period in the emergency department (ED) at Massachusetts General Hospital. Patients were included in the study if they were at least 18 years of age and were on warfarin per electronic health records. Patients were excluded if they had received both FFP and 4F-PCC during the same visit. The primary outcome was the frequency of thromboembolism within 30 days of 4F-PCC or FFP. Secondary outcomes included time to thromboembolic event and in-hospital mortality.ResultsThree hundred and thirty-six patients met the inclusion criteria. Thromboembolic events within 30 days of therapy occurred in seven patients (2.7%) in the FFP group and 14 patients (17.7%) in the 4F-PCC group (p=<0.001). Death occurred in 39 patients (15.2%) who received FFP and 18 patients (22.8%) who received 4F-PCC (p=0.115). Since the 4F-PCC group was treated disproportionately for central nervous system (CNS) bleeding, a subgroup analysis was performed including patients requiring reversal due to CNS bleeds that received vitamin K. The primary outcome remained statistically significant, occurring in four patients (4.1%) in the FFP group and nine patients (14.1%) in the 4F-PCC group (p=0.02).ConclusionOur study found a significantly higher risk of thromboembolic events in patients receiving 4F-PCC compared to FFP for urgent warfarin reversal. This difference remained statistically significant when controlled for CNS bleeds and administration of vitamin K.
Highlights
Warfarin is a potent anticoagulant used for the prevention and treatment of venous and arterial thrombosis
Thromboembolic events within 30 days of therapy occurred in seven patients (2.7%) in the fresh frozen plasma (FFP) group and 14 patients (17.7%) in the 4-factor prothrombin complex concentrate (4F-PCC) group (p=
Our study found a significantly higher risk of thromboembolic events in patients receiving 4F-PCC compared to FFP for urgent warfarin reversal
Summary
Warfarin is a potent anticoagulant used for the prevention and treatment of venous and arterial thrombosis. Various agents can be used for emergent warfarin reversal, including fresh frozen plasma (FFP) and 4-factor prothrombin complex concentrate (4F-PCC). Both FFP and 4F-PCC are generally considered safe; both agents contain coagulation factors and have the potential to provoke a thromboembolic event. 4F-PCC reduces the INR more quickly and is preferred as a first-line agent for warfarin reversal in intracranial hemorrhage, the most disabling form of major bleeding.[5,6,7,8,9] Both FFP and 4F-PCC are generally considered safe; both agents contain coagulation factors and have the potential to provoke a thromboembolic event. Clinical trials have compared the efficacy and safety of FFP and 4F-PCC, there is sparse data comparing the risk of thromboembolism between the two agents outside the clinical trial setting, using “real world” data. 6,7,10,11,12,13,14
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have